drugset / Trial / NCT07035821

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

NCT07035821

Phase 3 Not yet recruiting 100 enrolled Shanghai Children's Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.

Timeline

Start
2025-07-01
Primary completion
2026-06-30
Completion
2026-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule Oral